Hangzhou Jiuyuan Genetic Biopharmaceutical (HKG:2566) said the Hong Kong bourse approved its application to convert and list 136.3 million unlisted shares in the city, according to a Friday filing.

Twelve investors hold the relevant shares and account for 56.44% of the drugmaker's total issued shares.

Upon completion of the conversion and listing, the pharma company's issued share capital will comprise 245.3 million H shares.